14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological Response
Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
Patients with HCV genotype 2 or 3 infection who have a rapid virological response to
treatment are randomised to either 14 or 24 weeks HCV treatment. Our hypothesis is that there
is no important difference in effect between the two treatment effect.